VAGINAL MICROBIOTA: FIRST LINE OF DEFENSE AGAINST HPV
Oral Lactobacillus Crispatus M247* administration, enhances HPV clearance 1
HPV clearance 1
Dominance of CST I 1
Baseline
At 90 days of treatment
100
100
90
90
100%
94.3%
80
80
70
70
60
60
68.6%
50
50
40
40
30
30
29%
28.6%
20
20
10
10
CST I 0%
CST II 0%
2.9% CST II
2.9% 2.9%
0
0
CST I
Baseline
90 days
CST III
CST IV
CST III
CST IV
Lactobacilli protect the women's genital tract from pathogens by: 2-4
pH
Adhesion at cervical epithelium avoiding the anchorage of pathogens 2
Decrease of pH through lactic acid production 2-4
Production of antimicrobial compounds 2
*M247 is the probiotic strain of PharmExtracta's Crispact® product
1. DI Pierro, Francesco et al. “Oral administration of Lactobacillus crispatus M247 to papillomavirus-infected women: results of a preliminary, uncontrolled, open trial.” Minerva obstetrics and gynecology vol. 73,5 (2021): 621-631. doi:10.23736/S2724-606X.21.04752-7 2. Łaniewski, Paweł et al. “The microbiome and gynaecological cancer development, prevention and therapy.” Nature reviews. Urology vol. 17,4 (2020): 232-250. doi:10.1038/s41585-020-0286-z 3. Brotman, Rebecca M et al. “Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection.”The Journal of infectious diseases vol. 210,11 (2014): 1723-33. doi:10.1093/infdis/jiu330 4. Kyrgiou, Maria et al. “Does the vaginal microbiota play a role in the development of cervical cancer?.” Translational research : the journal of laboratory and clinical medicine vol. 179 (2017): 168-182.doi:10.1016/j.trsl.2016.07.004
Made with FlippingBook - Online magazine maker